Covalon Technologies has been growing earnings at an average annual rate of 40.5%, while the Biotechs industry saw earnings growing at 30% annually. Revenues have been growing at an average rate of 21.7% per year. Covalon Technologies's return on equity is 3.7%, and it has net margins of 3.1%.
Key information
40.48%
Earnings growth rate
39.75%
EPS growth rate
Biotechs Industry Growth
17.04%
Revenue growth rate
21.69%
Return on equity
3.70%
Net Margin
3.10%
Last Earnings Update
31 Dec 2025
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Covalon Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:CVAL.F Revenue, expenses and earnings (CAD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
32
1
15
1
30 Sep 25
33
2
14
1
30 Jun 25
33
2
15
1
31 Mar 25
34
4
15
2
31 Dec 24
35
5
14
2
30 Sep 24
31
3
15
2
30 Jun 24
29
-1
16
2
31 Mar 24
26
-3
16
2
31 Dec 23
25
-5
18
1
30 Sep 23
27
-4
17
1
30 Jun 23
25
-6
17
1
31 Mar 23
23
-7
17
1
31 Dec 22
19
-9
16
1
30 Sep 22
18
-9
15
1
30 Jun 22
19
-4
11
1
31 Mar 22
21
-2
10
1
31 Dec 21
22
0
9
1
30 Sep 21
20
0
8
1
30 Jun 21
7
-4
2
1
31 Mar 21
7
-4
3
1
31 Dec 20
8
-8
7
1
30 Sep 20
14
-8
11
1
30 Jun 20
26
-8
23
1
31 Mar 20
27
-12
26
1
31 Dec 19
35
-8
28
1
30 Sep 19
34
-9
29
1
30 Jun 19
34
-6
26
1
31 Mar 19
35
-1
23
1
31 Dec 18
28
-1
19
1
30 Sep 18
27
2
17
1
30 Jun 18
30
3
19
1
31 Mar 18
28
1
19
1
31 Dec 17
28
2
18
1
30 Sep 17
27
2
18
1
30 Jun 17
18
-1
14
1
31 Mar 17
15
-1
12
1
31 Dec 16
10
-3
9
1
30 Sep 16
7
-3
6
1
30 Jun 16
8
-2
6
1
31 Mar 16
7
-2
5
1
31 Dec 15
9
0
5
1
30 Sep 15
8
-1
5
1
30 Jun 15
7
-1
4
1
Quality Earnings: CVAL.F has high quality earnings.
Growing Profit Margin: CVAL.F's current net profit margins (3.1%) are lower than last year (13.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CVAL.F has become profitable over the past 5 years, growing earnings by 40.5% per year.
Accelerating Growth: CVAL.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CVAL.F had negative earnings growth (-79.3%) over the past year, making it difficult to compare to the Biotechs industry average (40.2%).
Return on Equity
High ROE: CVAL.F's Return on Equity (3.7%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/07 05:24
End of Day Share Price
2026/05/05 00:00
Earnings
2025/12/31
Annual Earnings
2025/09/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Covalon Technologies Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.